抄録
The effect of immunoglobulin for preventing post-transfusion hepatitis was studied. Following the method proposed by Creutzfeldt et al. and Katz et al., γ-globulin for intravenous use was added to blood in vitro before transfusion.
One hundred and sixty patients who had undergone cardiovascular surgery and blood transfusion from January 1978 to Feburuary 1980 were divided into 2 groups. 52 patients (control group) were transfused without γ-globulin. The remaining 108 patients (treated group) were performed transfusion following addition of 250mg or 500mg of Gamma-Venin to each 200ml of blood in vitro. Hepatic function test were performed for all the patients once a week at least 8 weeks after the first transfusion.
The incidence of post-transfusion hepatitis was as follows:
1) 16 cases (30.8%) in control group and 16 cases (14.8%) in treated group conforming to criterion of post-transfusion hepatitis (I)
2) 7 cases (13.5%) in control group and 5 cases (4.6%) in treated group conforming to criterion of post-transfusion hepatitis (II)
3) 4 cases (7.7%) in control group and none in treated group conforming to criterion of posttransfusion hepatitis (III) respectively.
Thus the incidence of post-transfusion hepatitis was significantly lower in treated group for all 3 criteria.
There was no significant difference between control group and treated group in incubation period and duration of post-transfusion hepatitis.
At present, it is impossible to exclude the carrier of non-A, non-B hepatitis virus from blood donors, therefore, the addition of immunoglobulin to blood in vitro is considered to be the most reasonable and reliable method to prevent post-transfusion hepatitis.
